Innovation Pharmaceuticals Inc (IPIX)

[DoubleJ23]

CTIX specifically mentions the possibility of a box warning in its SEC documents (I want to say this was revealed last summer). Overall side effects should be greatly reduced as the dose for psoriasis is much lower than what is used for HIV, but the hypersensitivity issue still remains. The box warning is still probable because of the hypersensitivity issue, but Prurisol patients will get a test to determine if they are hypersensitive before the drug is administered (If I recall correctly, dmattingly posted an email from Leo on this very item, I could look it up if you want...). While the test does greatly reduce the incidence of adverse reactions, it does not eliminate it. It will be interesting to see after the trials, whether or not the adverse reactions continue to occur or if the incidence is low enough to not warrant the warning. This will only be knows after trial data is released.